Literature DB >> 21549695

Involvement of NCAM and FGF receptor signaling in the development of analgesic tolerance to morphine.

Wakako Fujita-Hamabe1, Kazuo Nakamoto, Shogo Tokuyama.   

Abstract

This study examined the involvement of neural cell adhesion molecule (NCAM), a member of the immunoglobulin superfamily, in the development of tolerance to morphine. Furthermore, we focused on fibroblast growth factor (FGF) receptor and protein kinase C (PKC)-α as part of the intracellular signal transduction pathways underlying NCAM stimulation. The development of analgesic tolerance to morphine was gradually observed during daily treatment of morphine (10mg/kg, s.c.) for 5 days. Morphine treatment gradually and significantly decreased the NCAM expression levels. However it returned to normal levels immediately after re-treatment of morphine. Treatment of AS-ODN against NCAM completely inhibited analgesic tolerance to morphine. Protein expression levels of PKC-α were significantly increased by repeated morphine treatment in a NCAM-AS-ODN-reversible manner. Interestingly, alterations of protein interactions between NCAM and FGF receptor were observed under repeated morphine treatment. In addition, SU5402 (2 μg/mouse, i.c.v.), an inhibitor of FGF receptor, completely abolished the development of analgesic tolerance to morphine. Furthermore, κ-opioid receptor stimulation using U-50,488H, a κ-opioid receptor agonist, or establishment of formalin-induced chronic pain can completely suppress these changes in protein expression levels of NCAM and PKC-α and inhibit development of analgesic tolerance to morphine. These findings suggest that NCAM and its interaction with FGF receptor in the mechanism of up-regulation of PKC-α may contribute to the development of analgesic tolerance to morphine. Chronic pain or κ-opioid receptor stimulation could modulate these phenomena and suppress the development of analgesic tolerance to morphine.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549695     DOI: 10.1016/j.ejphar.2011.04.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Growth Factor Signaling Regulates Mechanical Nociception in Flies and Vertebrates.

Authors:  Roger Lopez-Bellido; Stephanie Puig; Patrick J Huang; Chang-Ru Tsai; Heather N Turner; Michael J Galko; Howard B Gutstein
Journal:  J Neurosci       Date:  2019-05-28       Impact factor: 6.167

2.  Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-β Signaling, Not μ-Opioid Receptor Internalization.

Authors:  S Puig; K E Barker; S R Szott; P T Kann; J S Morris; H B Gutstein
Journal:  Mol Pharmacol       Date:  2020-07-28       Impact factor: 4.436

3.  Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction.

Authors:  Rachel L Kember; Rachel Vickers-Smith; Heng Xu; Sylvanus Toikumo; Maria Niarchou; Hang Zhou; Emily E Hartwell; Richard C Crist; Christopher T Rentsch; Lea K Davis; Amy C Justice; Sandra Sanchez-Roige; Kyle M Kampman; Joel Gelernter; Henry R Kranzler
Journal:  Nat Neurosci       Date:  2022-09-28       Impact factor: 28.771

4.  Fibroblast Growth Factor 2 Modulates Hippocampal Microglia Activation in a Neuroinflammation Induced Model of Depression.

Authors:  Ming-Ming Tang; Wen-Juan Lin; Yu-Qin Pan; Ying-Cong Li
Journal:  Front Cell Neurosci       Date:  2018-08-08       Impact factor: 5.505

5.  Genome-Wide Association Study of Opioid Cessation.

Authors:  Jiayi W Cox; Richard M Sherva; Kathryn L Lunetta; Emma C Johnson; Nicholas G Martin; Louisa Degenhardt; Arpana Agrawal; Elliot C Nelson; Henry R Kranzler; Joel Gelernter; Lindsay A Farrer
Journal:  J Clin Med       Date:  2020-01-09       Impact factor: 4.241

6.  EGFR Signaling Causes Morphine Tolerance and Mechanical Sensitization in Rats.

Authors:  Stephanie Puig; Courtney L Donica; Howard B Gutstein
Journal:  eNeuro       Date:  2020-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.